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Introduction

Eosinophilia is not an uncommon
finding on a routine complete blood
count (CBC) during a primary care
visit. The differential diagnosis is
varied including allergic/atopic
disease, drug reaction, infection,
inflammatory conditions, and
malignancy.
We present a case of
extreme progressive eosinophilia
secondary to a malignancy which
would be of interest to the
primary care clinician.

Imaging
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Increased eosinophils in the peripheral
blood of a patient with eosinophilia
(Wright-Giemsa stain 400X)

Case History

Discussion

Discussion

An 80-year-old male was incidentally
found to have leukocytosis on routine
labs. White blood cell (WBC) was 27.5
K/ul with eosinophilia 4.3 K/ul (normal
range 0-0.6 Kul) and
Hemoglobin/Platelet counts were
normal. Patient was asymptomatic.
Denied history of medication change
or allergy. Chest X-Ray (CXR)
followed by Computed tomography
(CT) showed 5 cm pulmonary mass
with mediastinal lymphadenopathy.
Patient developed progressively
enlarging left neck mass, hoarseness,
weight loss and decreased appetite in
the next 3 weeks. WBC increased
steeply to 65 K/ul with eosinophil
count - 18.5 K/ul.
CT neck revealed a large
heterogeneous mass of the thyroid
extending to the trachea, esophagus,
and mediastinum.
Patient decided not to proceed with
further diagnostic workup and
management given his age and
comorbidities.

Eosinophilia can be
asymptomatic or present with
nonspecific symptoms like cough,
fatigue, skin rash or neuropathy.
Eosinophilia work up starts with a
comprehensive history detailing
travel history, exposure to well
water/spring water, analysis of
past medical history to include
asthma, atopy and especially
medication history. Physical
exam with attention to
atopy/eczema and skin rash is
vital. Work up may include a
CBC, peripheral blood smear,
stool test (for ova and parasite),
IgE/tryptase levels and evaluation
for occult malignancy (CXR is an
ideal first step). Further testing
with Bone marrow biopsy and CT
scans is a consideration if a clear
diagnosis is not achieved.

Life-threatening complications
of untreated hypereosinophilia include
thromboembolism, endomyocardial
fibrosis, cognitive disturbances,
and respiratory failure. Incidence
of eosinophilia is 1% in
malignant tumors.
Malignancy encompasses
hematological cancers (acute
leukemia, chronic myeloid leukemia,
systemic mastocytosis,
lymphoid neoplasms) and solid
tumors (lung, thyroid, breast
and gastrointestinal tract
cancers). Eosinophilia suggests
advanced disease in solid tumors
and portends poor prognosis.
Paraneoplastic eosinophilia has been
reported in thyroid cancer (sclerosing
muco-epidermoid) and lung cancer
(squamous
and adenocarcinoma). Pathophysiolog
y of eosinophilia in solid tumors is
related to bone marrow stimulation
through cytokines (interleukin5, granulocyte-macrophage colonystimulating factor, and interleukin2). Primary eosinophilia responds to
steroids and hydroxyurea. Treating the
underlying malignancy is the
cornerstone of paraneoplastic
eosinophilia management.

